The purpose of this study is to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the counter nicotinamide riboside (NR) using magnetic resonance spectroscopy (MRS).
This is an open-label, nonrandomized study, primary outcome is to correlate blood and tissue measurements of NAD+ and metabolites. Investigators will recruit 12 men and 12 women aged 18-35 years and 12 men/12 women aged 70 years or older. Whole blood, serum and urine will be collected and MRS measurements performed at baseline and 30 days for in vivo determinations of nicotinamide adenine dinucleotide (NAD) and its metabolites. After baseline measurements, participants will take 1000 mcg of NR orally daily for 30 days. Baseline measurements will be repeated on days 29 and 30. Assessors of outcomes will be blinded to study status of participants.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
48
Oral Nicotinamide Riboside (NR)
Penn Medicine
Philadelphia, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Nicotinamide adenine dinucleotide (NAD) measurement in brain MRI
NAD level will be assessed in brain MRI
Time frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)
NAD measurement of calf MRI
NAD level in calf MRI
Time frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)
Serum NAD metabolites
Measurement of serum metabolites of Nicotinamide adenine dinucleotide
Time frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with NR
Urine NAD metabolites
Measurement of urine NAD metabolites
Time frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.